IRIS
TAGLIAMENTO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.463
AS - Asia 1.286
NA - Nord America 1.223
SA - Sud America 109
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 8.101
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.242
US - Stati Uniti d'America 1.156
SG - Singapore 418
CN - Cina 310
VN - Vietnam 198
BD - Bangladesh 197
BR - Brasile 68
FR - Francia 65
HK - Hong Kong 59
FI - Finlandia 50
DE - Germania 32
CA - Canada 26
GB - Regno Unito 16
JP - Giappone 16
AR - Argentina 13
IN - India 13
NL - Olanda 12
PH - Filippine 11
MX - Messico 10
ID - Indonesia 7
CH - Svizzera 6
IQ - Iraq 6
RU - Federazione Russa 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
CO - Colombia 5
CR - Costa Rica 5
EC - Ecuador 5
HN - Honduras 5
MY - Malesia 5
PY - Paraguay 5
TH - Thailandia 5
TR - Turchia 5
DZ - Algeria 4
JM - Giamaica 4
TW - Taiwan 4
UY - Uruguay 4
AT - Austria 3
CL - Cile 3
GT - Guatemala 3
IE - Irlanda 3
IL - Israele 3
KR - Corea 3
RS - Serbia 3
SA - Arabia Saudita 3
SE - Svezia 3
SV - El Salvador 3
UA - Ucraina 3
VE - Venezuela 3
AL - Albania 2
BE - Belgio 2
EG - Egitto 2
ES - Italia 2
GR - Grecia 2
HR - Croazia 2
JO - Giordania 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PK - Pakistan 2
PL - Polonia 2
RO - Romania 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BB - Barbados 1
BS - Bahamas 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MF - Saint Martin 1
MK - Macedonia 1
MM - Myanmar 1
MQ - Martinica 1
NI - Nicaragua 1
PA - Panama 1
PT - Portogallo 1
RE - Reunion 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
VI - Stati Uniti Isole Vergini 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.101
Salva come PNG Salva come JPEG
Città #
Genoa 2.968
Genova 927
Vado Ligure 630
Rapallo 474
Singapore 203
San Jose 192
Ashburn 158
Council Bluffs 73
Lauterbourg 61
St Louis 60
Ho Chi Minh City 58
Hong Kong 55
Beijing 52
Hanoi 47
New York 47
Helsinki 46
Milan 30
Los Angeles 27
Boardman 25
Rome 21
Frankfurt am Main 19
Santa Clara 18
Bordighera 14
Chicago 14
Da Nang 14
Dallas 14
Houston 12
Tokyo 12
Atlanta 10
Tianjin 10
Buffalo 9
City of London 9
Naples 8
Miami 7
Philadelphia 7
São Paulo 7
Brooklyn 6
Mexico City 6
Piscataway 6
Amsterdam 5
Baghdad 5
Bologna 5
Cincinnati 5
Haiphong 5
Las Vegas 5
Muggia 5
Orem 5
Phủ Lý 5
Tashkent 5
Turin 5
Asunción 4
Billings 4
Brescia 4
Florence 4
Florianópolis 4
Guangzhou 4
Hải Dương 4
Jersey City 4
Johannesburg 4
Kingston 4
Memphis 4
Mumbai 4
Padua 4
Phoenix 4
Princeton 4
Seattle 4
Tampa 4
Thái Bình 4
Zurich 4
Bari 3
Calgary 3
Catania 3
Charlotte 3
Columbus 3
Dhaka 3
Dublin 3
Guatemala City 3
Hefei 3
Hyattsville 3
Istanbul 3
Lappeenranta 3
New Delhi 3
Nuremberg 3
Palermo 3
Richmond 3
San José 3
San Pedro Sula 3
San Salvador 3
Schiffdorf 3
Shanghai 3
Stuttgart 3
Taoyuan District 3
Thái Nguyên 3
Vienna 3
Villasanta 3
Afragola 2
Alexandria 2
Amman 2
Ancona 2
Arlington 2
Totale 6.575
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 241
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 225
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 207
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 201
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 181
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 171
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 169
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 168
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 163
Radiomic detection of EGFR mutations in NSCLC 161
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 156
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 149
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 148
Novel emerging molecular targets in non-small cell lung cancer 143
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 141
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 141
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test 141
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 139
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 137
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 136
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 135
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 135
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 133
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 132
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 131
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 129
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 128
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 126
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study 121
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 121
Update on the management of breast cancer during pregnancy 118
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 117
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 116
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 116
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 115
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 110
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 107
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 103
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 101
Call for ensuring cancer care continuity during COVID-19 pandemic 101
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 100
Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient 94
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 91
Performance of the oncomineTM Lung cfDNA assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice 88
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 87
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 87
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab 85
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer 82
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 82
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer 73
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity 73
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 71
The evolving scenario of cancer care provision across the COVID-19 pandemic in Europe 69
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates 69
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis” 67
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 67
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 66
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 65
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies 64
VISTA: A Promising Target for Cancer Immunotherapy? 64
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 63
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives 60
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies 57
null 57
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 56
New emerging targets in cancer immunotherapy: The role of VISTA 52
Expected medium- And long-term impact of the COVID-19 outbreak in oncology 50
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 50
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer 48
Oncological care organisation during COVID-19 outbreak 48
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey 47
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 46
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 46
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction 43
Does perioperative immunotherapy reduce the risk of second primary cancers? 41
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors 39
Heterogeneity of treatment effects in malignant pleural mesothelioma 35
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer 33
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study 33
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma 30
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer 27
Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer 22
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 20
Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 19
The use of immunotherapy in older patients with advanced non-small cell lung cancer 19
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives 18
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients 18
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases 13
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease 13
Time to rethink platinum choices in the era of immunotherapy in lung cancer 13
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer 12
Tackling Non–Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes 10
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX 6
Totale 8.401
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.335
article - articoli 31.044
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 65
Totale 62.444
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022394 38 13 9 29 21 25 16 79 32 52 21 59
2022/2023567 43 53 5 48 93 81 7 46 97 12 75 7
2023/2024475 11 33 11 55 27 85 36 36 17 42 39 83
2024/20251.854 78 102 43 115 220 199 202 342 104 91 194 164
2025/20264.167 350 154 580 397 383 224 497 210 300 426 342 304
2026/2027319 319 0 0 0 0 0 0 0 0 0 0 0
Totale 8.401